Takeda opposes purchasers' motion for judgment in US antitrust case over Amitiza
MLex Summary: Takeda Pharmaceuticals told a US federal court that Amitiza purchasers are unable to establish that evidence points so strongly and overwhelmingly in their favor that no reasonable jury could...To view the full article, register now.
Already a subscriber? Click here to view full article